NCT03033914 2026-02-17
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
Clinical Trials
12 trialsNCT02979522 2025-11-10
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Takeda
Phase 1/2 Active not recruiting
NCT03331341 2025-08-05
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
University of Washington
Phase 1/2 Completed
NCT03277924 2024-08-13
ImmunoSarc
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2 Completed
NCT02076646 2022-04-14
A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
Philogen S.p.A.
Phase 1/2 Unknown
NCT00615160 2021-10-06
PTK/ZK in Disseminated Malignant Melanoma
University Hospital Schleswig-Holstein
Phase 1/2 Terminated
NCT00715793 2017-10-03
UPCI-07-008
University of Pittsburgh
Phase 1/2 Completed
NCT01133977 2016-10-10
E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
Eisai Inc.
Phase 1/2 Completed
NCT00354523 2014-12-17
Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00597038 2013-12-16
A Phase I/II Study of Dasatinib and Dacarbazine
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT00023738 2013-06-24
Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00496223 2011-02-23
A Phase I/II Study of Sunitinib and Dacarbazine
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated